A Multicenter, Open-label Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat, in Combination With Ibrutinib, in Subjects With Relapsed or Refractory Lymphomas

Trial Profile

A Multicenter, Open-label Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat, in Combination With Ibrutinib, in Subjects With Relapsed or Refractory Lymphomas

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Abexinostat (Primary) ; Ibrutinib
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Nov 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2020 as per NCT.
    • 19 Nov 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2020 as per NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top